glp 1 dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Machine learning designs new GCGR/GLP-1R
Description
Tiwari AK, Kumar V, Yadav DP, et al
Adding GIPR co-agonism (as in tirzepatide and retatrutide) introduces additional Gs signalling from a second receptor type expressed on adipocytes, beta cells, and hypothalamic neurones
Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of Head-to-head clinical trials
Mnnist, S., Kontto, J., Kataja-Tuomola, M., Albanes, D., & Virtamo, J
